Technical Analysis for CHRS - Coherus BioSciences, Inc.

Grade Last Price % Change Price Change
grade D 13.94 -1.69% -0.24
CHRS closed down 1.69 percent on Friday, February 15, 2019, on 65 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical CHRS trend table...

Date Alert Name Type % Chg
Feb 15 Outside Day Range Expansion 0.00%
Feb 15 Wide Bands Range Expansion 0.00%
Feb 15 Down 3 Days in a Row Weakness 0.00%
Feb 14 MACD Bearish Signal Line Cross Bearish -1.69%
Feb 14 Narrow Range Bar Range Contraction -1.69%
Feb 14 Weak + Overbought Other -1.69%
Feb 14 Wide Bands Range Expansion -1.69%
Feb 14 Overbought Stochastic Strength -1.69%
Feb 13 Narrow Range Bar Range Contraction -2.31%
Feb 13 NR7 Range Contraction -2.31%

Older signals for CHRS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Medicine Biotechnology Biopharmaceutical Immunology Chemotherapy Breast Cancer Rheumatoid Arthritis Psoriasis Immunosuppressants Recombinant Proteins Treatment Of Breast Cancer Biosimilar Etanercept
Is CHRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.66
52 Week Low 8.32
Average Volume 701,684
200-Day Moving Average 14.4806
50-Day Moving Average 11.3846
20-Day Moving Average 13.313
10-Day Moving Average 14.235
Average True Range 0.6618
ADX 34.28
+DI 24.5663
-DI 16.1502
Chandelier Exit (Long, 3 ATRs ) 12.8346
Chandelier Exit (Short, 3 ATRs ) 12.8154
Upper Bollinger Band 15.6124
Lower Bollinger Band 11.0136
Percent B (%b) 0.64
BandWidth 34.543679
MACD Line 0.8085
MACD Signal Line 0.8593
MACD Histogram -0.0508
Fundamentals Value
Market Cap 715.76 Million
Num Shares 51.3 Million
EPS -2.60
Price-to-Earnings (P/E) Ratio -5.36
Price-to-Sales 3.37
Price-to-Book 17.33
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.08
Resistance 3 (R3) 15.11 14.77 14.89
Resistance 2 (R2) 14.77 14.48 14.75 14.83
Resistance 1 (R1) 14.35 14.30 14.18 14.32 14.76
Pivot Point 14.01 14.01 13.92 13.99 14.01
Support 1 (S1) 13.59 13.72 13.42 13.56 13.12
Support 2 (S2) 13.25 13.54 13.23 13.05
Support 3 (S3) 12.83 13.25 12.99
Support 4 (S4) 12.80